Rituxan (rituximab)
RITUXAN (rituximab) – a CD20-directed cytolytic antibody indicated for the treatment of patients with rheumatoid arthritis, Granulamatosis, and certain types of leukemias and lymphomas. Rituxan binds specifically to the antigen CD20, a hydrophobic transmembrane protein that is located on pre-B and mature B lymphocytes. The antigen is expressed on 90% of B-cell non=Hodgkins lymphomas (NHL) […]